Novavax (NVAX)
(Delayed Data from NSDQ)
$14.94 USD
+1.09 (7.87%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $14.83 -0.11 (-0.74%) 7:22 PM ET
2-Buy of 5 2
D Value D Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$14.94 USD
+1.09 (7.87%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $14.83 -0.11 (-0.74%) 7:22 PM ET
2-Buy of 5 2
D Value D Growth F Momentum F VGM
Zacks News
Novavax (NVAX): Strong Industry, Solid Earnings Estimate Revisions
by Zacks Equity Research
Novavax (NVAX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Coronavirus Drug & Vaccine: 4 Companies Leading From the Front
by Nilanjan Banerjee
The present scenario has brightened up prospects for companies working on potential drugs and vaccines to combat the pandemic.
Novavax (NVAX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Novavax (NVAX) closed the most recent trading day at $13.86, moving -1.21% from the previous trading session.
Coronavirus Vaccine Race Intensifies: 3 Stocks in Focus
by Ekta Bagri
Given the urgent need for preventing the spread of COVID-19 in future, let's take a look at the companies developing vaccines for the same.
Biotech Stocks & ETFs to Gain on Progress in COVID-19 Vaccine Development
by Sweta Jaiswal, FRM
The rampant race to introduce a vaccine for the COVID-19 is creating near-term opportunities, making the biotech sector a lucrative space for investments.
Translate Bio, Sanofi to Jointly Develop Coronavirus Vaccine
by Zacks Equity Research
Translate Bio (TBIO) gains on collaboration with Sanofi for a mRNA vaccine development for COVID-19.
Novavax Rallies as Influenza Vaccine Meets All Goals in Study
by Zacks Equity Research
Novavax's (NVAX) NanoFlu, the influenza vaccine candidate for adults aged 65 years and older, meets all the primary and secondary endpoints in late-stage study. Shares rise.
Biotech Stock Roundup: HOTH & IMV to Develop Coronavirus Vaccines, & More
by Zacks Equity Research
The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.
Company News for Mar 25, 2020
by Zacks Equity Research
Companies in the news are: NVAX, GSAT, INFO, GNW
Aytu BioScience to Issue Coronavirus Rapid Test in North America
by Zacks Equity Research
Aytu BioScience (AYTU) expands the right to distribute and commercialize the COVID-19 IgG/IgM rapid test across the United States, Canada and Mexico. Stock jumps.
Hoth Surges on Collaboration With Voltron for COVID-19 Vaccine
by Zacks Equity Research
Hoth (HOTH) soars following a joint venture with Voltron Therapeutics for a vaccine for COVID-19.
Axsome Expedites Completion Timeline of AD Study on AXS-05
by Zacks Equity Research
Axsome (AXSM) speeds up the evaluation time of AXS-05 under the phase II/III ADVANCE-1 study for Alzheimer's disease agitation to ensure safety of patients amid the COVID-19 pandemic.
Gilead's HCV Drug Epclusa Gets FDA Nod for Expanded Age Group
by Zacks Equity Research
The FDA approves Gilead's (GILD) sNDA for Epclusa to treat chronic hepatitis C infection in children aged six years and above or weighing at least 17 kg.
Emergent (EBS) to Help Vaxart Develop Coronavirus Vaccine
by Zacks Equity Research
Emergent BioSolutions (EBS) teams up with Vaxart to support development of the latter's oral vaccine candidate for treating coronavirus disease.
The Zacks Analyst Blog Highlights: Moderna, Novavax and Regeneron Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Moderna, Novavax and Regeneron Pharmaceuticals
5 Low-Beta Stocks to Tackle Coronavirus-Led Market Volatility
by Sreoshi Bera
The current volatility in equity market calls for investment in these five low-beta stocks.
Top Ranked Momentum Stocks to Buy for March 19th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, March 19th
Is Novavax (NVAX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (NVAX) Outperforming Other Medical Stocks This Year?
Hopes of a COVID-19 Vaccine Buoy Drug Makers: 3 Solid Buys
by Tirthankar Chakraborty
Shares of Moderna soared higher after the company dosed a patient with a vaccine against the novel coronavirus in the Phase 1 study. This, calls for investing in companies racing to develop a vaccine against COVID-19
These 10 Drug Companies are Testing a Coronavirus Vaccine
by Madeleine Johnson
As the coronavirus pandemic continues to spread, some of the biggest drug companies are moving closer to finding a vaccine.
Biotech Sector in Focus as Coronavirus Spreads Panic
by Ekta Bagri
The outbreak of COVID-19 has brought the volatile biotech sector under the spotlight as both large and small companies rush to develop treatments and vaccines to combat this pandemic.
Emergent (EBS) Begins Development of Treatments for COVID-19
by Zacks Equity Research
Emergent (EBS) starts developing two plasma-derived product candidates for the treatment and prevention of coronavirus disease.
3 Small Biotechs Provide Coronavirus Drug Development Updates
by Kinjel Shah
Several drug/biotech companies are working on making new antibodies, drugs, and vaccines to prevent and treat COVID-19.
Novavax (NVAX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Novavax (NVAX) delivered earnings and revenue surprises of -4.63% and 120.95%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stock Roundup: NVAX, CANF Up on Coronavirus Treatment Updates & More
by Zacks Equity Research
The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.